header logo image


Page 719«..1020..718719720721..730740..»

Evaluating the Impact of Diabetes on the Performance of Algorithms for the Detection of AMI Without ST-Elevation – The Cardiology Advisor

February 5th, 2020 11:41 pm

The performance of the European Society of Cardiology (ESC) algorithm, ESC 0/1-h, in ruling out acute myocardial infarction (AMI) without ST-elevation was comparable in patients with and without diabetes mellitus (DM), according to a study published in Diabetes Care.

The ESC 0/1-h and 0/3-h algorithms are used to diagnose patients with suspected acute non-ST-elevation myocardial infarction (NSTEMI). The levels of high-sensitivity cardiac troponin (hs-cTn) are often chronically elevated in individuals with DM, rendering it difficult to identify NSTEMI in this patient population. Investigators sought to assess whether the presence of DM affects the diagnostic abilities of 2 ESC algorithms in patients presenting to the emergency department with symptoms indicative of AMI.

In this secondary analysis of 2 studies, the Biomarkers in Acute Cardiac Care (BACC) and stenoCardia trials (ClinicalTrials.gov identifiers NCT02355457 and NCT03227159, respectively), 3,681 patients (mean age, 64.0 years; 64.2% men) with prospectively evaluated suspected acute NSTEMI with (n=563) and without DM, were enrolled. Data from the Advantageous Predictors of Acute Coronary Syndromes study (APACE; n=2895; ClinicalTrials.gov identifier NCT00470587) were used to calculate and externally validate alternative cutoffs for the algorithms.

The levels of hs-cTn were measured at admission, 1 hour (only in the BACC study), and 3 hours (in both studies). Negative and positive predictive values (NPV and PPV, respectively) for NSTEMI were calculated for both algorithms. The studys primary safety outcome was the NPV for NSTEMI (ie, for ruling out the condition), and the primary efficacy outcome was the PPV for ruling in NSTEMI. The sensitivity and specificity of both algorithms were the studys secondary endpoints.

Of 563 participants with DM, 137 (24.3%) had comorbid acute NSTEMI, compared with 15.9% of patients without DM (P <.001). Participants with DM were older and had more cardiovascular risk factors and comorbidities.

The ESC 0/1-h algorithm had a comparable NPV for NSTEMI in patients with and without DM (absolute difference [AD], -1.50; 95% CI, -5.95 to 2.96; P =.54), but the ESC 0/3-h algorithm had a lower NPV in patients with vs without DM (AD, -2.27; 95% CI, -4.47 to -0.07; P =.004). The diagnostic performance to rule-in NSTEMI was comparable for patients with vs without DM with both algorithms: ESC 0/1-h (AD, -6.59; 95% CI, -19.53 to 6.35; P =.34) and ESC 0/3-h (AD, 1.03; 95% CI, -7.63 to 9.7; P =.88).

The sensitivity for ruling out NSTEMI was comparable in patients with vs without DM with both ESC0/1-h (AD, -0.9; 95% CI, -5.1 to 3.3; P =1.00) and ESC 0/3-h (AD, -4.0; 95% CI, -10.4 to 2.4; P =.19) algorithms. The specificity for ruling in NSTEMI was higher for patients without vs with DM when using both the ESC 0/1-h (AD, -6.9; 95% CI -12.5 to -1.2; P =.0035) and ESC 0/3-h (AD, -4.4; 95% CI, -8.2 to 0.6; P =.01) algorithms. The use of alternative cutoffs improved the PPV of both algorithms.

Study strengths include large sample sizes and external validation of proposed alternative cutoffs. Study limitations include the sole use of data from the BACC study to evaluate the 0/1-h algorithm, possible misclassification of AMI and DM, and a lack of accounting for disease duration.

Although alternative cutoffs might be helpful, patients with DM remain a high-risk population in whom identification of AMI is challenging and who require careful clinical evaluation, noted the authors.

Reference

Haller PM, Boeddinghaus J, Neumann JT, et al. Performance of the ESC 0/1-h and 0/3-h algorithm for the rapid identification of myocardial infarction without ST-elevation in patients with diabetes. Diabetes Care. 2019;43(2):460-467. doi: 10.2337/dc19-1327

See the original post:
Evaluating the Impact of Diabetes on the Performance of Algorithms for the Detection of AMI Without ST-Elevation - The Cardiology Advisor

Read More...

Type 2 Diabetes Apps Help With Modest Weight Loss, Review Finds – Everyday Health

February 5th, 2020 11:41 pm

Mobile apps might help some obese or overweight people with type 2 diabetes shed excess pounds (lbs), but a recent review also suggests that results may be modest at best.

For thepaper, published in January 2020 in Obesity, researchers looked at changes in waist circumference, weight, and body mass index (BMI) in 2,129 people with type 2 diabetes who participated in one of 14 different clinical trials testing a variety of mobile apps for diabetes self-management. These trials randomly assigned some participants to use apps, while others did not, and interventions lasted between 3 and 12 months.

By the end of the trials, people who used diabetes apps lost an average of 0.84 kilograms (about 1.9 lbs) more than participants who didnt. With mobile apps, people also reduced their waist circumference by 1.35 centimeters (about inch) more on average.

BMI appeared lower with apps than without these tools, but the difference was too small to rule out the possibility that it was due to chance.

Reductions in weight, waist circumference, and BMI appeared more pronounced when people were obese and when participants used apps in combination with other interventions designed to promote healthy eating and exercise habits. Some of the trials in the analysis allowed participants to pursue other approaches to weight loss with or without also using a mobile app to manage diabetes.

Mobile application interventions combined with other behavior components lead to a larger magnitude of weight loss, says senior study author Mingzi Li, PhD, of Peking University in Beijing. However, the mobile application functionalities do not moderate weight loss significantly.

Face-to-face or supervised lifestyle modification programs have long been considered a cornerstone of diabetes care, Dr. Li and colleagues wrote. Obesity is a risk factor for developing diabetes and for experiencing potentially serious complications, like blindness, amputations, kidney failure, heart attacks, and strokes.

People who lose at least 5 percent of their body weight in the first year after a diabetes diagnosis may cut their 10-year risk of events like heart attacks and strokes roughly in half, according to a study published in May 2019 in Diabetologia.

And people who lose less weight may still see benefits. Patients with diabetes who lost no more than 2.5 percent of their body weight, for example, were able to lower their blood sugar, cholesterol, and blood pressure, according to a review and meta-analysis published in June 2016 in Obesity Reviews.

RELATED: The Best Apps for Managing Diabetes

In the current study, people typically lost less than 2.5 percent of their body weight. This doesnt seem like much, but it might be enough for them to see improvements in blood sugar, cholesterol, and blood pressure, Li and colleagues wrote.

Weight loss didnt appear to be influenced by whether apps had certain features, like tracking physical activity, logging food, counting calories, monitoring weight, or monitoring or recording blood sugar levels.

This might be because all studied mobile apps had four to five functionalities on average, and it is therefore difficult to distinguish between individual effects, Li said.

At the start of the trials, participants were 58 years old on average and had an average BMI of 30, meaning they typically had obesity.

People who started out with a higher BMI appeared to benefit more from using apps. For each additional unit in BMI as measured at the start of the trials, people using apps achieved of 0.15 kilograms (about 0.3 lbs) more weight loss on average.

RELATED: Most Type 2 Diabetes Apps Fall Short in Helping Users Manage Blood Sugar

Even though the current study pooled results from randomized controlled clinical trials considered the gold standard for medical research there are still some limitations.

One big drawback is that the studies didnt provide long-term weight loss outcomes, particularly because so many people who lose weight struggle to keep it off.

Another limitation is that the results dont show what types of apps or features within apps might help the most with weight loss.

More research is needed to determine whether apps might help people who dont have time or money to do face-to-face appointments with psychologists, nutritionists, or other clinicians who might help them develop and stick to a weight loss plan, Li and colleagues pointed out.

Its possible, they argue, that apps might help some busy people stick with weight loss efforts because its easier and more convenient to use a smartphone every day to monitor progress than it is to go to checkups.

People with diabetes who try and fail to lose substantial amounts of weight using only an app shouldnt be discouraged that they dont get results, says Susan Roberts, PhD, a professor of nutrition at Tufts University in Boston and founder of iDiet.

Dont feel guilty if an app isnt helping you, Dr. Roberts says. They dont help the average person much based on these results, and there are other ways to lose weight.

Whether or not people use apps, regular monitoring of progress with lifestyle changes and weight loss efforts is one key to success, according to the Centers for Disease Control and Prevention.

Besides mobile app interventions, there has been a growing evidence that interventions like step counters could be effective in weight loss as well, Li said. If combined with additional behavior change components, including multidisciplinary diabetes care management or health coaching, they will be more effective.

RELATED: Smart Health: I Tried Noom for Weight Loss and It Worked

See more here:
Type 2 Diabetes Apps Help With Modest Weight Loss, Review Finds - Everyday Health

Read More...

Native Health offers cooking classes to address high rates of diabetes – Cronkite News

February 5th, 2020 11:41 pm

By Grace Lieberman, Cronkite News | Tuesday, Feb. 4, 2020

PHOENIX Cooking equipment at the ready, Mallory Smith stands before a table loaded with fresh greens, nuts and fruit.

Has anyone used the apple slicer before? she asks the dozen people gathered this weekday morning at Native Health. Might take a little bit of practice.

Over the next hour, Smith chopped, mixed and scooped as she demonstrated how to make a chicken Waldorf salad as part of a new class to encourage diabetes-friendly cooking to help diabetics manage their blood sugar.

A lot of people in the Native American community and in the Phoenix community, they get diagnosed with diabetes but arent necessarily educated on it, Smith said. Having this class helps them find out what diabetes is, what kind of foods they can eat with diabetes, what can help them for their overall health.

Video by Jordan Elder/Cronkite News

The 20-week course, which is free and open to anyone, is held morning and evening every Thursday through June 4. Each week, Smith demonstrates a new recipe, and participants will go home with free groceries to replicate the dishes at home.

Food for Thought is part of Native Healths diabetes management program for the Native American community. Michelle Hill, a certified diabetes educator at Native Health, said the goal is to show patients that eating properly can be easy, accessible and economical.

More than 30 million Americans have diabetes, according to the American Diabetes Association. That includes 695,000 Arizonans or 12.5% of the adult population.

Both nationally and in Arizona, Native Americans have the highest rates of the disease, followed by blacks and Hispanics. More than 19% of adult Native Americans in the state have been diagnosed, the Arizona Department of Health Services reports.

Type 1 diabetes is a condition in which the body does not produce any insulin, which helps regulate blood sugar. In the more common type 2 diabetes, the body produces insulin but does not use it properly. Some people only need to maintain a healthy diet and exercise regimen to manage the disease, while others might need insulin injections or other medicines.

Michelle Hill, a registered dietician and certified diabetes educator, explains how to read nutrition labels at Native Health in Phoenix on Jan. 23. (Photo by Alicia Moser/Cronkite News)

In order to properly regulate their blood sugar, diabetics are cautioned against eating foods high in processed sugar, such as white bread, sugary cereals and flavored yogurt and drinks. Hill told participants they should not be afraid to eat the natural sugar found in whole fruits.

Glorene Barton learned about Food for Thought from her health care providers during a recent appointment at Native Health.

I was asking about snacks, because Im a diabetic and I forgot to bring a snack with me. So she told me about this class that might be interesting for me, Barton said. I learned a few different things about eating and grams and carbs and things of that nature. It was interesting.

Another participant, Marla Wilson, said her son motivates her to keep up with a healthy diet. She thought this program was a great opportunity to learn how.

I have a son whos very health-conscious. So Im sure hell like it, too, because we were just talking about eating more salads and the health benefit, Wilson said.

Hill kicked off the morning by providing some tips about managing diabetes. Participants learned they can test their bodies reaction to new foods by trying them over a few days, then checking their blood sugar levels two hours later each time.

The finished product: a chicken Waldorf salad made with fresh produce. (Photo by Alicia Moser/Cronkite News)

Then it was time to get cooking. Smith guided the group through the process of making the salad, explaining some basic knife work, how to substitute in healthy ingredients and portioning.

The ingredient that surprised people the most was nonfat yogurt, which was used along with lemon juice to dress the salad. Smith said yogurt is an excellent substitute for less healthful ingredients, such as sour cream.

At the end, participants were able to take home both dry goods and fresh produce funded by the Mobilize AZ project from Blue Cross Blue Shield of Arizona.

Being diabetic is a very expensive way of being, and so this is a plus, Wilson said. We get what we need to make our dinner tonight.

Added Barton: Its the learning thats more important to me. Im tired of eating the same thing all the time, so this is great.

Follow Cronkite News on Twitter.

See more here:
Native Health offers cooking classes to address high rates of diabetes - Cronkite News

Read More...

Gestational Diabetes: The Treatment Controversy Rages On – Medscape

February 5th, 2020 11:41 pm

EXPERT ANALYSIS FROM DPSG-NA 2019

WASHINGTON Pharmacologic treatment of gestational diabetes remains controversial, with the American College of Obstetricians and Gynecologists and the American Diabetes Association firmly recommending insulin as the preferred first-line pharmacologic therapy, and the Society of Maternal-Fetal Medicine more accepting of metformin as a "reasonable and safe first-line" alternative to insulin and stating that there are no strong data supporting metformin over the sulfonylurea glyburide.

If there's one main take-away,Mark B. Landon, MD,said at the biennial meeting of the Diabetes in Pregnancy Study Group of North America, it was that "the primary concern" about the use of oral agents for treating gestational diabetes mellitus (GDM) is that there is limited long-term follow-up of exposed offspring.

"The claim that long-term safety data are not available for any oral agent is probably the most valid warning [of any of the concerns voiced by professional organizations]," said Dr. Landon, Richard L. Meiling professor and chair of the department of obstetrics and gynecology at The Ohio State University Wexner Medical Center, Columbus.

Otherwise, he said, there are not enough data to firmly prioritize the drugs most commonly used for GDM, and "the superiority of insulin over oral agents simply remains questionable."

ACOG's 2017 level A recommendation for insulin as the first-line option when pharmacologic treatment is needed for treating GDM(Obstet Gynecol. 2017;130[1]:e17-37)was followed in 2018 by another updated practice bulletin on GDM (Obstet Gynecol. 2018;131[2]:e49-64) that considered several meta-analyses published in 2017 and reiterated a preference for insulin.

Those recent meta-analyses of pharmacologic treatment of GDM show that the available literature is generally of "poor trial quality," and that studies are small and not designed to assess equivalence or noninferiority,Mark Turrentine, MD,chair of ACOG's committee on practice bulletins, said in an interview. "Taking that into account and [considering] that oral antidiabetic medications are not approved by the Food and Drug Administration [for the treatment of GDM], that they cross the placenta, and that we currently lack long-term neonatal safety data ... we felt that insulin is the preferred treatment."

In its 2017 and 2018 bulletins, ACOG said that metformin is a "reasonable alternative choice" for women who decline insulin therapy or who may be unable to safely administer it (a level B recommendation). The 2018 practice bulletin mentions one additional factor: affordability. "Insurance companies aren't always covering [insulin]," said Dr. Turrentine, of the department of obstetrics and gynecology, Baylor College of Medicine, Houston. "It's a challenge no question."

ACOG says glyburide should not be recommended as a first-line pharmacologic treatment, "because, in most studies, it does not yield outcomes equivalent to insulin or metformin," Dr. Turrentine emphasized.

Dr. Landon took issue with ACOG's stance on the sulfonylurea. "Frankly, I think this [conclusion] is debatable," he said. The trend in the United States "at least after the 2017 ACOG document came out" has been toward use of metformin over glyburide when an oral agent is [used], but "I think glyburide has been unfairly trashed. It probably still has a place."

As Dr. Landon sees it, research published in 2015 put a damper on the use of glyburide, which "had become the number one agent" after an earlier, seminal trial, led by Oded Langer, MD, had shown equivalent glycemic control in about 400 women with GDM who were randomized to receive either insulin or glyburide (N Engl J Med. 2000;343;1134-8). The trial was not powered to evaluate other outcomes, but there were no significant differences in neonatal complications, Dr. Landon said.

One of the 2015 studies a large, retrospective, population-based study of more than 9,000 women with GDM treated with glyburide or insulin showed a higher risk of admission to the neonatal intensive care unit (relative risk, 1.41), hypoglycemia in the newborn (RR, 1.40), and large-for-gestational age (RR, 1.43) with glyburide, compared with insulin (JAMA Pediatr. 2015;169[5]:452-8).

A meta-analysis of glyburide, metformin, and insulin showed significant differences between glyburide and insulin in birth weight, macrosomia (RR, 2.62), and neonatal hypoglycemia (RR, 2.04;BMJ. 2015;350;h102). However, "this was basically a conglomeration of studies with about 50 [individuals] in each arm, and in which entry criteria for the diagnosis of GDM were rather heterogeneous," said Dr. Landon. "There are real problems with this and other meta-analyses."

The authors of a 2018 multicenter, noninferiority, randomized, controlled trial of about 900 women concluded that their study failed to show that the use of glyburide, compared with insulin, does not result in a greater frequency of perinatal complications. The authors also wrote, however, that the "increase in perinatal complications [with glyburide] may be no more than 10.5%, compared with insulin" (JAMA. 2018;319[17]:1773-80).

That increase, Dr. Landon said, was "not an absolute 10%, but 10% of the complication rate, which probably translates to about 2%." The only component of a composite outcome (including macrosomia, hypoglycemia, and hyperbilirubinemia) that was significantly different, he noted, was hypoglycemia, which affected 12.2% of neonates in the glyburide group and 7.2% in the insulin group.

Glyburide's role may well be substantiated in the future, Dr. Landon said during a discussion period at the meeting, through research underway at the University of Pittsburgh aimed at tailoring treatment to the underlying pathophysiology of a patient's GDM.

TheMATCh-GDMstudy (Metabolic Analysis for Treatment Choice in GDM) is randomizing women to receive usual, unmatched treatment or treatment matched to GDM mechanism metformin for predominant insulin resistance, glyburide or insulin for predominant insulin secretion defects, and one of the three for combined mechanisms. The study's principal investigator,Maisa Feghali, MD,of the department of obstetrics, gynecology, and reproductive sciences at the University of Pittsburgh, stressed in a presentation on the study that GDM is a heterogeneous condition and that research is needed to understand the impact of GDM subtypes on treatment response.

Concerns about the impact of metformin on short-term perinatal outcomes focus on preterm birth, Dr. Landon said. The only study to date that has shown an increased rate of prematurity, however, is the "seminal" Metformin in Gestational Diabetes (MiG) trial led by Janet A. Rowan, MBChB, that randomized 751 women with GDM in Australia and New Zealand to treatment with metformin or insulin. The researchers found no significant differences between a composite of neonatal complications but did establish that severe hypoglycemia was less common in the metformin group and preterm birth was more common (N Engl J Med. 2008;358:2003-15).

A 2016 systematic review and meta-analysis of short- and long-term outcomes of metformin, compared with insulin, found that metformin did not increase preterm delivery (Diabet Med. 2017;34[1]:27-36). And while the 2015 BMJ meta-analysis found that metformin was associated with higher rates of preterm birth (RR, 1.50), the increased risk "was all driven by the Rowan study," Dr. Landon said. The 2015 meta-analysis also found that metformin was associated with less maternal weight gain and fewer infants who were large for gestational age.

Metformin is also tainted by high rates of failure in GDM. In the 2008 Rowan study, 46% of patients on metformin failed to achieve glycemic control. "But this is a classic half-full, half-empty [phenomena]," Dr. Landon said. "Some people say this isn't good, but on the other hand, 54% avoided insulin."

Indeed, the Society of Maternal-Fetal Medicine (SMFM), in its 2018statementon the pharmacologic treatment of GDM, said that oral hypoglycemic agents that are used as monotherapy work in "more than half" of GDM pregnancies. The need for adjunctive insulin to achieve glycemic control ranges between 26% and 46% for women using metformin, and 4% and 16% for women using glyburide, it says.

In the society's view, recent meta-analyses and systemic reviews "support the efficacy and safety of oral agents," and "although concerns have been raised for more frequent adverse neonatal outcomes with glyburide, including macrosomia and hypoglycemia, the evidence of benefit of one oral agent over the other remains limited."

The society says that the difference between its statement and the ACOG recommendations is "based on the values placed by different experts and providers on the available evidence," and it adds that more long-term data are needed.

But as Dr. Landon said, the SMFM is "a little more forgiving" in its interpretation of a limited body of literature. And clinicians, in the meantime, have to navigate the controversy. "The professional organizations don't make it easy for [us]," he said. At this point, "insulin does not cross the placenta, and the oral agents do cross it. Informed consent is absolutely necessary when choosing oral agents for treating GDM."

Of greater concern than neonatal outcomes are the potential long-term issues for offspring, Dr. Landon said. On the one hand, it is theorized that metformin may protect beta-cell function in offspring and thereby reduce the cross-generational effects of obesity and type 2 diabetes. On the other hand, it is theorized that the drug may cause a decrease in cell-cycle proliferation, which could have "unknown fetal programming effects," and it may inhibit the mTOR signaling pathway, thus restricting the transport of glucose and amino acids across the placenta, he said. (Findings from in vitro research have suggested that glyburide treatment in GDM might be associated with enhanced transport across the placenta, he noted.)

Long-term follow-up studies of offspring are "clearly needed," Dr. Landon said. At this point, in regard to long-term safety, he and other experts are concerned primarily about the potential for obesity and metabolic dysfunction in offspring who are exposed to metformin in utero. They are watching follow-up from Dr. Rowan's MiG trial, as well as elsewhere in the literature, on metformin-exposed offspring from mothers with polycystic ovary syndrome.

A follow-up analysis of offspring from the MiG trial found that children of women with GDM who were exposed to metformin had larger measures of subcutaneous fat at age 2 years, compared with children of mothers treated with insulin alone, but that overall body fat was the same, Dr. Landon noted. The investigators postulated that these children may have less visceral fat and a more favorable pattern of fat distribution (Diab Care. 2011;34:2279-84).

A recently published follow-up analysis of two randomized, controlled trials of women with polycystic ovary syndrome is cause for more concern, he said. That analysis showed that offspring exposed to metformin in utero had a higher body mass index and an increased prevalence of obesity or overweight at age 4 years, compared with placebo groups (J Clin Endocrinol Metab. 2018;103[4]:1612-21).

That analysis of metformin-exposed offspring in the context of polycystic ovary syndrome was published after the SMFM statement, as was another follow-up analysis of MiG trial offspring this one, at ages 7-9 years that showed an increase in weight, size, and fat mass in one of two subsets analyzed, despite no difference in large-for-gestational age rates between the metformin- and insulin-exposed offspring (BMJ Open Diabetes Res Care. 2018;6[1]: e000456).

In 2018, a group of 17 prominent diabetes and maternal-fetal medicine researchers cited these findings in a response to the SMFM statement and cautioned against the widespread adoption of metformin use during pregnancy, writing that, based on "both pharmacologic and randomized trial evidence that metformin may create an atypical intrauterine environment ... we believe it is premature to embrace metformin as equivalent to insulin or as superior to glyburide, and that patients should be counseled on the limited long-term safety data and potential for adverse childhood metabolic effects" (Am J Obstet Gynecol. 2018;219[4]:367.e1-7).

This article first appeared on MDEdge.com.

Read more:
Gestational Diabetes: The Treatment Controversy Rages On - Medscape

Read More...

How These Diabetes Experts Stabilized Their Blood Sugar With Food Alone – mindbodygreen.com

February 5th, 2020 11:41 pm

"I was doing the exact opposite of a traditional diabetes modelI was eating more carbohydrate energy than I'd ever eaten before," Khambatta explains. "I was eating 600 grams of carbohydrate energy per day, and my insulin use got cut by 35 to 40%."

"I started eating lots of fruits and vegetables," Barbaro adds. "I increased my carbohydrate content and had a 22-to-1 carbohydrate-insulin ratio." In case you aren't familiar with the technical language, that means his insulin sensitivity changed by 600%.

It's important to note the distinction between whole carbs and processed, refined carbs here (it's always good to have a reminder!). Barbaro and Khambatta are partial to the four main carbohydrate categories: fruits,starchy vegetables, beans and legumes, and whole grains.

"The type of carbohydrate you eat absolutely matters," Khambatta says. That said, these experts are encouraging you to eat sweet potatoes, not french fries.

There is some nuance (Khambatta is partial to chickpeas and lacinato kale, while Barbaro loves his sweet potatoes), but the two agree that carbs are essential for long-term health. In terms of their favorite carbs to have on their plates, they agree on fruit as the No. 1 option. "Bananas, mangoes, papayas, pears, jackfruit, you name it. That's our personal favorite, no question."

Even if you don't necessarily suffer from type 1 diabetes, these whole carbohydrate-rich foods are packed with vitamins, fiber, and phytochemicals that increase your overall nutrient densitysomething we all ultimately want, no?

Read more from the original source:
How These Diabetes Experts Stabilized Their Blood Sugar With Food Alone - mindbodygreen.com

Read More...

Menopause Hormone Therapy Found to Delay Type 2 Diabetes – Medscape

February 5th, 2020 11:41 pm

EXPERT ANALYSIS FROM THE WCIRDC 2019

LOS ANGELES Although menopausal hormone therapy is not approved for the prevention of type 2 diabetes because of its complex balance of risks and benefits, it should not be withheld from women with increased risk of type 2 diabetes who seek treatment for menopausal symptoms, according toFranck Mauvais-Jarvis, MD.

"During the menopause transition, women accumulate metabolic disturbances, including visceral obesity, systemic inflammation, insulin resistance, dyslipidemia, and hypertension," Dr. Mauvais-Jarvis, director of the Tulane Diabetes Research Program at Tulane University Health Sciences Center, New Orleans, said at the Annual World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease. "They also lose muscle mass. Some of these abnormalities are partially explained by chronological aging, but they are also caused by estrogen deficiency. There's a synergism between aging and estrogen deficiency."

The best evidence of this synergy comes from older trials. Nearly 30 years ago, researchers examined the association between postmenopausal hormone use and the subsequent incidence of noninsulin dependent diabetes in a prospective cohort of 21,028 postmenopausal U.S. women aged 30-55 years, who were enrolled in the Nurse's Health Study and followed for 12 years (Ann Epidemiol. 1992;2[5]:665-73). They found that study participants on hormone therapy experienced a 20% reduction in the incidence of type 2 diabetes. In a more recent trial, researchers examined the association between use of hormone therapy and new-onset diabetes in 63,624 postmenopausal women who were enrolled in the prospective French cohort of the Etude Epidemiologique de Femmes de la Mutuelle Gnrale de l'Education Nationale (E3N) and followed for 15 years (Diabetologia. 2009;52[10]:2092-100). It found that study participants on hormone therapy experienced a 20% reduction in the incidence of type 2 diabetes.

In the Heart and Estrogen/Progestin Replacement Study, researchers evaluated the effect of hormone therapy on fasting glucose level and incident diabetes in 2,763 postmenopausal women with coronary heart disease (Ann Intern Med. 2003;138[1]:1-9). At 20 U.S. centers, the study participants received 0.625 mg of conjugated estrogen plus 2.5 mg of medroxyprogesterone, or placebo, and were followed for 4 years. The researchers found that the use of hormone therapy reduced the incidence of diabetes by 35%.

According to Dr. Mauvais-Jarvis, the strongest data come from the Women's Health Initiative (WHI), a randomized, double-blind trial that compared the effect of daily 0.625 mg conjugated estrogen plus 2.5 mg medroxyprogesterone acetate with that of placebo during 5.6 years of follow-up (Diabetologia. 2004; 47[7]:1175-87). It showed a 20% decrease in the incidence of diabetes at 5 years. More recently, researchers found that, whether WHI participants took estrogen plus medroxyprogesterone or estrogen alone, the protection from diabetes was present (N Engl J Med. 2016;374:803-6).

In 2006, researchers published results from a meta-analysis of 107 trials in an effort to quantify the effects of hormone therapy on components of metabolic syndrome in postmenopausal women (Diabetes Obes Metab. 2006;8[5]:538-54). In women without diabetes, hormone therapy reduced the HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) score by 13% and incidence of type 2 diabetes by 30%. In women with diabetes, hormone therapy reduced fasting glucose by 11% and HOMA-IR by 36%.

The mechanisms by which estrogens improve glucose homeostasis are yet to be fully understood. "One of the most important [mechanisms] is a decrease in abdominal fat, which improves insulin resistance and systemic inflammation," Dr. Mauvais-Jarvis said. "However, in the WHI, it was clear that the improvement in HOMA-IR was independent from the body weight and fat. Estrogen has also been found to increase insulin clearance and sensitivity, increase glucose disposal and effectiveness and decrease sarcopenia. There are fewer than 20 studies looking at beta-cell function. Half of them have shown that estrogen improves insulin secretion."

Route of estrogen administration also comes into play. For example, oral estrogens increase liver exposure to estrogen, increase triglycerides, and increase clotting factors. "That is why oral estrogens are not indicated in women with risk of deep venous thrombosis," Dr. Mauvais-Jarvis said. "They also increase inflammatory factors like C-reactive protein. Advantages are that they decrease LDL cholesterol levels and increase HDL cholesterol levels more than transdermal estrogen does."

The main advantage with transdermal delivery of estrogen, he continued, is that it does not raise triglycerides, clotting factors, or inflammatory factors, and it confers less exposure to the liver. "That's why it's the preferred way of administration in women who are obese, who have a risk of DVT, or who have cardiovascular risk factors," he said. "It has a lower suppression of hepatic glucose production, it increases circulating estradiol, and the delivery to nonhepatic tissue is increased. The oral form of estrogen is cheaper, compared with the transdermal form, though. This is a factor that is always taken into account."

Dr. Mauvais-Jarvis and colleagues were first to evaluate the effect of conjugated estrogens plus bazedoxifene in mice (Mol Metab. 2014;3[2]:177-90). "The idea was that by combining estrogen and bazedoxifene, you have the beneficial effect of estrogen in the tissues but you block estrogen in the breast and in the uterus, and therefore, you prevent the risk of cancer," he said. "We found that tissue-selective estrogen complexes with bazedoxifene prevent metabolic dysfunction in female mice. It increased energy expenditure and decreased fatty liver."

In a subsequent pilot study, he and his colleagues assessed the effect of 12 weeks' treatment with bazedoxifene/conjugated estrogens, compared with placebo, on glucose homeostasis and body composition in 12 postmenopausal women (NCT02237079). "We did not find any significant alterations in the IVGTT [Intravenous Glucose Tolerance Test] but we observed improved fasting beta-cell function and serum glucose in menopausal women with obesity," Dr. Mauvais-Jarvis said (J Endocr Soc. 2019;3[8]:1583-94).

In a separate, randomized, double-blind, placebo-controlled, crossover trial that he and his colleagues performed in eight postmenopausal women with obesity, the primary endpoint was insulin action as measured by a two-step hyperinsulinemic-euglycemic clamp. Secondary endpoints were body composition, basal metabolic rate, ectopic fat, and metabolome. "We did not find any difference in systemic insulin action, ectopic fat, or energy expenditure," he said. "But we found something very interesting. We did a metabolic analysis and found that oral estrogens increase hepatic de novo lipogenesis and liver triacylglycerol production. In other words, the oral estrogens were increasing [triacylglycerol] synthesis from glucose, but it does not accumulate in the liver."

Dr. Mauvais-Jarvis disclosed that he has received research support from the National Institutes of Health, the American Diabetes Association, the Department of Veterans Affairs, and Pfizer.

This story originally appeared onMDedge.com.

Follow this link:
Menopause Hormone Therapy Found to Delay Type 2 Diabetes - Medscape

Read More...

WVU project works toward preventing blindness in diabetic patients – WBOY.com

February 5th, 2020 11:41 pm

MORGANTOWN, W.Va. The risk of going blind is all too real for diabetics but a WVU project is hoping to mitigate that risk for West Virginians.

The West Virginia Practice-Based Research Network is the organization behind trying to stop or limit diabetic retinopathy, or blindness as a result of diabetes. Stacey Whanger, the Networks assistant director said their work has been going on since 2016 and that they have been engaging primary care providers to offer a new screening for diabetic patients.

The patients that need the screenings from physicians are the ones that are not necessarily seen by an eye doctor, Whanger said, so theyre actually providing care to folks who may not have access to an early screening.

Its recommended that patients with diabetes have yearly eye exams because diabetic retinopathy starts very smallvery subtle changes so patients may not recognize that its happening until the disease is later in the stages, Whanger said. So its important to get that early screening done so then treatment can be provided earlier to the patient and hopefully have better success and save the sight as long as possible.

According to a WVU press release, it is projected that one in three Americans with diabetes will experience diabetic retinopathy by the year 2050. The projection may be frightening but early detection reduces the risk of severe vision loss by 90 percent.

Whanger said the project is also trying to reach out to diabetic patients from the moment when they are diagnosed with diabetes in order to get them in touch with an eye care specialist. The reason being that a regular doctor cannot treat diabetic retinopathy, they can only do an initial screening to see if the eyes are normal.

Moving forward, Whanger said, they are hoping to expand the project to more sites around the state.

We cover a good portion of areas around the state but were hoping to expand to other primary care sites to really deliver the care to patients that are not receiving their annual eye exams and to be able to provide that care to them, Whanger explained. We also are really creating a network across the state between eye care professionals and primary care providers so this could really extend to other diseases that have systematic and ophthalmic conditions and how it goes hand in hand. It just works as a nice partnership between all the different providers that a patient might come in contact with.

See more here:
WVU project works toward preventing blindness in diabetic patients - WBOY.com

Read More...

Local teen with type 1 diabetes invited to State of the Union Address – WKBW-TV

February 5th, 2020 11:41 pm

BUFFALO, N.Y. (WKBW) Fourteen-year-old Ben Cornell was diagnosed with type 1 diabetes when he was ten years old. He's now advocating for research funding to find a cure for the autoimmune illness.

He will be among the guests attending Tuesday night's State of the Union Address after receiving an invite from Congressman Tom Reed.

"It's a struggle it's not very easy, and it's always like, there. You never really get a break," he said. "I didn't want to have it anymore, and just anything anybody can do to help it just makes us that much closer."

Supporting Cornell is Edward Dickey, Board President of the WNY chapter of the Juvenile Diabetes Research Foundation. His daughter has type 1 as well.

"Thankfully there's technologies that have come along in the last ten years that have made life easier to live with but it is by no means a cure," he said. "Insulin is by no means a cure, we need to continue to fund research and try to find a cure for diabetes."

Another major issue type one diabetics face is insulin affordability. The price of the vital drug has skyrocketed over the last decade, leading people to crossing over the border to Canada to get it for a cheaper price, or more dangerously - rationing their insulin.

But Dickey is hopeful a cure will be found.

"In the last six months the Special Diabetes Program, the SDP, was approved by Congress and gave us $97 million over the last six moths to help find a cure for diabetes," he said.

Dickey said it's important to get a multi-year approval of that agreement so JDRF does not have to worry about research money.

Continued here:
Local teen with type 1 diabetes invited to State of the Union Address - WKBW-TV

Read More...

Information Update – Apotex Inc. recalls certain lots of the diabetes medication APO-Metformin ER (extended release) 500 mg tablets – BioSpace

February 5th, 2020 11:41 pm

OTTAWA, Feb. 5, 2020 /CNW/ -

Summary

IssueApotexInc.. is recalling eight lots of its 500 mg extended release metformin tablets ("APO-Metformin ER") because they contain a nitrosamine impurity called N-nitrosodimethylamine (NDMA) above the acceptable limit. Apotex Inc. has tested all lots of its 500 mg extended release tablets; only the affected lots are being recalled (see table below). There are also alternative metformin products on the Canadian market manufactured by other companies.

Metformin is a prescription drug used to control high blood sugar in patients with type 2 diabetes.

Individuals taking metformin, including a recalled product,should not stoptaking it unless they have spoken to their health care provider as the risks from not having adequate diabetes treatment outweigh any possible effects of exposure to the levels of NDMA found in the recalled products.

NDMA is classified as a probable human carcinogen. We are all exposed to low levels of nitrosamines through a variety of foods (such as smoked and cured meats, dairy products and vegetables), drinking water and air pollution. NDMA is not expected to cause harm when ingested at low levels. A person taking a drug that contains NDMA at or below the acceptable level every day for 70 years is not expected to have an increased risk of cancer.

In December 2019, Health Canadacommunicatedthat it is assessing the issue of NDMA in metformin products, after some metformin products available outside Canada were detected to contain NDMA above the acceptable limit. The Department asked companies to test their metformin products and is conducting testing in its own laboratories. Health Canada is also working closely with international regulatory partners, including the U.S. Food and Drug Administration and the European Medicines Agency, to inform its assessment. Health Canada continues to assess this issue, and will update the table below and inform Canadians should any additional recalls be necessary.

Health Canada has beenworkingto address the issue of NDMA and other nitrosamine impurities found in certain medications since the summer of 2018. Health Canada continues to work closely with international regulatory partners to address the issue. The Department will take action if a new risk to Canadians is identified, and will continue to inform the public of new safety information.

Who is affectedPatients who are taking an affected metformin drug.

What consumers should do

Affected productsThe following is a list of metformin drugs being recalled in Canada at this time:

Company

Product Name/ActivePharmaceutical Ingredient(API)

DIN

Strength

Lot

Expiry

Apotex Inc.

APO-Metformin ER(Metformin HydrochlorideExtended-Release Tablets)

02305062

500 mg

NV3242

04/2020

NV3244

04/2020

NV3245

04/2020

NV3243

04/2020

NV3247

04/2020

NV3248

04/2020

PX5334

01/2021

PX5335

01/2021

Related links

galement disponible en franais

SOURCE Health Canada

Read more here:
Information Update - Apotex Inc. recalls certain lots of the diabetes medication APO-Metformin ER (extended release) 500 mg tablets - BioSpace

Read More...

Generex Biotechnology Subsidiary Olaregen Therapeutix Receives VAC Approval and Ships Excellagen to the Arizona Indian Health Service – Yahoo Finance

February 4th, 2020 12:50 pm

MIRAMAR, Fla., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (GNBT) is pleased to announce that the companys subsidiary Olaregen Therapeutix, an emerging regenerative medicine company, has begun shipping Excellagen to the Indian Health Services in Arizona, following approval by the value added committee (VAC). Native American Indian adults are almost three times more likely to have diabetes and 2.5 times more likely to die from the complications of diabetes than the majority of other Americans. Excellagen wound conforming gel matrix is FDA cleared to manage 17 types of wounds including diabetic foot ulcers and venous leg ulcers, which are prevalent in the diabetic patient population. The Indian Health Service (IHS), an agency within the U.S. Department of Health and Human Services, provides care to over 2.2 million Native Americans in more than 560 recognized tribes across the country.

Anthony J. Dolisi, President and Chief Executive Officer of Olaregen said, We are excited that Excellagen has been approved by the Indian Health Services Value Added Committee, which not only enables us to begin selling Excellagen in Arizona, but which also opens the door to VAC approval across the IHS. We continue to make gains in the VA hospitals, where Excellagen is achieving some fantastic results for veterans who are dealing with hard to heal wounds, and we expect to achieve a national footprint by the end of the year. Additionally, we have begun the VAC approval process in the private sector and have just signed a new hospital in Texas.

About Generex Biotechnology Corp. Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization and medical device companies with new and approved products.

About Olaregen TherapeutixOlaregen Therapeutix, Inc. is a regenerative medicine company focused on the development, manufacturing and commercialization of products that fill unmet needs in the current wound care market. Generex aims to provide advanced healing solutions that substantially improve medical outcomes while lowering the overall cost of care.Olaregen's first product introduction, Excellagen (flowable dermal matrix) is a topically applied product for dermal wounds and other indications.Excellagen is a FDA 510K cleared device for a broad array of dermal wounds, including partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/ grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns and skin tears) and draining wounds, enabling Olaregen to market Excellagen in multiple vertical markets. Additionally, Excellagen can serve as an Enabling Delivery Platform for pluripotent stem cells, antimicrobial agents, small molecule drugs, DNA-Based Biologics, conditioned cell media and peptides. Olaregen's initial focus will be in advanced wound care including diabetic foot ulcers (DFU), venous leg ulcers and pressure ulcers. Future products focusing on innovative therapies in bone and joint regeneration comprise the current pipeline. Generex's mission is to become a significant force in regenerative medicine and advance the science of healing.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Story continues

Generex Contact:

Generex Biotechnology Corporation

Joseph Moscato 646-599-6222

Todd Falls 1-800-391-6755 Extension 222 investor@generex.com

Read more from the original source:
Generex Biotechnology Subsidiary Olaregen Therapeutix Receives VAC Approval and Ships Excellagen to the Arizona Indian Health Service - Yahoo Finance

Read More...

Malcolm McGregor, 5, who is fighting cancer, returns home to hero’s welcome – Wisconsin Rapids Tribune

February 4th, 2020 12:50 pm

Malcolm McGregor, 5, has been receiving treatment in Madison for neuroblastoma and returned home Sunday for the first time in four months. 24/7 Wall Street

GRAND RAPIDS Malcolm McGregor returned home to a heros welcome Sunday.

Family and friends erupted into cheers as the 5-year-old boy pulled into his driveway for the first time in four months.The McGregor family was escorted through Kellner and back to their Grand Rapids home by emergency vehicles from the Grand Rapids Police Department, Grand Rapids Fire Department, Wood County Sheriffs Department, Wood County Sheriff's Rescue, United Ambulance and others.

Groups of well-wishers also gathered along 80th Street in Kellner to welcome him home.

Malcolm, who has been battling stage 4 high-risk neuroblastoma since Dec. 24, 2018, spent the past four months at American Family Children's Hospitaland the Ronald McDonald House in Madison after receiving his second stem cell transplant in early October. The stay was initially expected to last only four weeks, but fevers, high blood pressure, infections and other life-threatening complications extended his stay.

RELATED:4-year-old Wisconsin Rapids boy fights cancer; family asks for cards and letters

RELATED:Wisconsin Rapids' 2019 People of the Year

Autoplay

Show Thumbnails

Show Captions

His parents, Jon and Tracy McGregor, have provided near-daily updates on Malcolms health struggles and victories during the stay on the Facebook group Malcolms MARVELous SUPER HERO cancer fighters, and on Saturday morningthey shared the happy news.

Four months Malcolm has been here. He missed four holidays. He almost died. Just thinking of writing this post has me all kinds of emotional but here we go. MALCOLM IS GOING HOME! Tracy McGregor wrote.

The McGregor family first shared Malcolms story with a Wisconsin Rapids Daily Tribune reporter in January 2019 when they asked people to send superhero-, Teenage Mutant Ninja Turtles- and PAW Patrol-inspired cards and letters to the boy as he fought cancer.

Soon, packages started arriving from across the United States and countries around the world.

I cannot begin to describe what its been like getting all these cards and packages, Tracy McGregor shared last year on Facebook. Malcolm loves going to the post office to pick them up! Thank you everyone!

That support has continued throughout Malcolms ongoing treatment. Community members have contributed over $12,000 to the familys GoFundMe account, donated items to the familys Amazon Wishlist and provided meals through Meal Train.

Hundreds of people also organized, volunteered at, donated to and attended the Malcolms Marvelous Superhero Cancer Crusade fundraiser in September at Wildhorse Saloon. The event included music, childrens activities, food and basket raffles.

Malcolm McGregor, 5, his family and members of local law enforcement organizations pose for a photo after Malcolm returned to his Grand Rapids, Wisconsin, home on Sunday, Feb. 2, 2020. He has been receiving treatment in Madison for stage 4 high-risk neuroblastoma for the past four months and returned home for the first time Sunday.(Photo: Jamie Rokus/USA TODAY NETWORK-Wisconsin)

In November, two members of the Wood County Sheriffs Rescue traveled to Madison to deliver Christmas cheer and gifts to Malcolm. And many local small-business owners and individuals have held fundraisers during the past year for the family, too.

Malcolm still will have to return to Madison monthly for immunotheraphy treatment through June and by mid-summer Malcolm will be done with treatment, Tracy McGregor wrote on Facebook.

People who wish to support the family can find needed items on their Amazon Wishlist or donate money through PayPal or GoFundMe.

Read or Share this story: https://www.wisconsinrapidstribune.com/story/news/crime/2020/02/02/malcolm-mcgregor-wisconsin-rapids-who-fighting-neuroblastoma-cancer-returns-home-heros-welcome/4640466002/

Read more here:
Malcolm McGregor, 5, who is fighting cancer, returns home to hero's welcome - Wisconsin Rapids Tribune

Read More...

Pet Wearables Are a Thing Now. Meet the Company That Wants to Collect Your Dog’s Data – Inc.

February 4th, 2020 12:48 pm

Editor's note:This article is part of Inc.'s 2020 Best Industries report.

In February 2017, Donovan got lost during a trip to the park. The skittish rescue dog's ownerCollette Bunton spent hours frantically searchingbefore the rat terrier mix finally found his own way home. To make sure her beloved pet would never get lost again, Buntondid some research on tracking devices, and decided tofitDonovan's collar with a device from a San Francisco-based startup called Whistle.

Fifteen months later, Bunton received a surprise phone call from Whistle: Want to be our CEO? "You probably don't know us very well," said co-founder Ben Jacobs, the voice on the other end. Bunton, a former Roku and Logitech executive, could only laugh: "I know you, and I have ideas on what kind of things we could do."

With Bunton at the helm, Whistle has become a leader in the fast-growing pet wearables industrybyrapidly improving its technology for monitoring customers' furry friends. Its flagship product line of Whistle Go devices--think of them as doggy Fitbits with cellular data-enabled location tracking--used to simply report a pet'slocation and number of miles walked per day. Now, that data gets crunched in real time to notify you through a smartphone appwhen subtle changes, like decreased activity or increased scratching, could indicate a health problem.

"You can, today, do things that you couldn't do six months ago," Bunton says. "There really is a true technology and use case inflection point that's happening."

Whistle's devices cost between $100 and $130, plus a subscription fee. Whistle declined to disclose specific revenue figures, but says it has seen consistent double-digit revenue growth rates since its launch eight years ago.Business intelligence platforms Owler and ZoomInfo estimate Whistle's annual revenue at$30 million and $38.9 million, respectively.

Developments like longer-lasting batteries and5G technology have spedadvancesin pet wearables, according to Ross Rubin, founder andprinciple analyst at consulting firm Reticle Research. The next step, he says, will be to more heavily saturate the market with affordable products:"It's just a question of finding the right combination of cost and functionality."

The pet wearables market--which includes GPS and fitness trackers, cameras, and smart clothing--is expected to grow to $1.7 billion in 2024 from $703 million in 2019, according to data from research firm MarketsandMarkets, andWhistle estimates thatmore than a milliondevices have been sold industry-wideto date.

Striving for customization

Whistle was founded in 2012 by Jacobs, fellow ex-Bain consultantSteven Eidelman, and software engineer Kevin Lloyd. Growing up, Jacobs had a German shepherd named Bear who seemed perfectly healthy, but justdays laterhad to be put down due to intestinal twisting.The founders'idea centered not around pet tracking, but on monitoring canine activity for predictive health, which could have caught Bear's issue sooner.

The startup attracted talent from companies like Apple and Google and grew thanks to more than $20 millionin venture capital funding--until 2016, when it was acquired by Mars Petcare for $117 million. Jacobs credits Mars, Inc.--one of the largest privately owned companies in the U.S.--for allowing Whistle to continue operating independently under its new corporate umbrella.

Between 2017 and 2019, the three co-founders left the company. Eidelman and Lloyd departed for other startups, and Jacobs became head of ventures and partnerships for Kinship, Mars's pet-focused startup accelerator and $100 million venture fund. Enter Bunton, who had runRoku's devices department as asenior vice president and general manager from 2012 to 2014.Upon joining Whistle in June 2018, Bunton immediately set about shifting the company's ethos to prepare for the industry's anticipated growth.

Strategically, that involved amping up services like data collection and analysis, in addition to the company'sfocus on hardware.For example: Whistle'sPet Insight Project, in which dog owners receive the company's newest product, aWhistle Fit,for free in return for access to that device's activity, calorie burn, and mileage data. Whistle hascollected data from more than 60,000 dogs across 900-plus different breeds and mixes, which Bunton hopes will ultimately enable the app to give individualized health recommendations for every dog. "Even in my house, what my other dog, Monster, needs and what Donovan needs are different," she says.

Bunton is keenly aware of the stigma associated with data collection, and says Whistle's largely Millennial staff of about 60 employees (and eight dogs) constantly weighs in on moral and ethical considerations of issues facing the business."It's [about] getting clearer vision on the things that matter to our users," she adds."And you do that through the personal information that they're willing to share with you."

A competitive pack

Whistle says it's "fast approaching" a majority of the industry's market share by units sold. (The companydeclined to provide unitsales figures.)Still, it faces stiff competition from startups like Kansas City, Missouri-based FitBark, founded in 2013,as well as larger companies like Garmin and Motorola, which both sell pet-monitoring devices and boastfinancial heft on par with Mars.

Bunton says Whistle aims to lead the pack by focusing on personalization, offering advice tailored for individual dog owners. That could include new products, features, and significant partnerships with dog-walking and other pet-service businesseslike Rover.com and Wag. "Our biggest challenge is really one of awareness--that it's a real, usable product and not a fun gadget," Bunton says. "That's a thing that takes time, and I'm not known to be the most patient woman in the world."

Published on: Feb 4, 2020

View post:
Pet Wearables Are a Thing Now. Meet the Company That Wants to Collect Your Dog's Data - Inc.

Read More...

Putting buybacks on hold, Pfizer’s CEO is plotting a string of important PhII deals in the year ahead. You’ve been alerted – Endpoints News

February 4th, 2020 12:48 pm

When the tech VCs at Andreessen Horowitz entered biotech 4.5 years ago with the $200 million bio fund I, the idea was simple and hubristic: Were not going to do biotech, Vijay Pande said at the time, keeping a16zs longtime stance. Instead, the bio fund is really about funding software companies in the bio space.

In the near-half decade since, they havent softened their rhetoric. Pande and general partner Jorge Condes frequent blog posts often have the tone ofBurning Man technofuturists. Talking of a foundational shift in biology, bio-revolution, and the meaning of life, and dropping koans like what is medicine? has turned them into the well-financed New Age mystics of an AI-driven and bioengineered future.

Today, Andreessen Horowitz is launching bio fund III and putting $750 million behind it more than funds I and II combined. Theyve added new partners, as they did before fund I and II, picking up technologist and entrepreneur Julie Yoo and Vineeta Agarwala, a GV and Broad Institute alumn. Itll take much of the same tack as the earlier funds, investing early and occasionally up to Series B, and pouring funds not only into therapeutics, but also diagnostics, synthetic biology and startups bringing biological advances into other sectors, such as agriculture.

But Conde tells Endpoints News that the group has learned a thing or two since fund I. Pande had talked about extending Moores law to biology through digital therapeutics but they were wrong. It wasnt just about software and artificial intelligence. It was about the long list of ways how biology was done, how drugs were discovered and how the whole healthcare system functions. It was biotechs that worked both with machine learning and wet labs, and founders conversant in both.

Since then, theyve invested in companies like Insitro that integrate AI as a core but not sole part of a drug development chain and Asimov, which is trying to use AI and other tech systems to design a genome from scratch. They even invested in EQRx, Alexander Boriseys startup trying to use me-too drugs to change pricing.

In October, Conde, Pande and Yoo published their most soaring blog post yet: Biology is Eating the World: A Manifesto. They wrote: We are at the beginning of a new era, where biology has shifted from an empirical science to an engineering discipline.

Before the funds launch, though, Conde told Endpoints were at the end of the beginning for that era.

He talked about what theyve learned since bio I, where biology and biotech is headed and how well know when the convergence between engineering and biology hes been prophesizing has arrived.

You called this the end of the beginning for a new era. What does that mean?

Unlock this story instantly and join 71,300+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

Continued here:
Putting buybacks on hold, Pfizer's CEO is plotting a string of important PhII deals in the year ahead. You've been alerted - Endpoints News

Read More...

Philly teachers grapple with illness, school building conditions – WHYY

February 4th, 2020 12:48 pm

Listen to The Why wherever you get your podcasts:Apple Podcasts|Google Podcasts|Stitcher|RadioPublic|TuneIn

By Avi Wolfman-Arent

On the day before Thanksgiving in 2015, veteran biology teacher Lynn Johnson made an unusual decision she decided not to clean up her classroom.

Her students had just completed a lab experiment, which would typically send her into a frenzy of tidying and straightening. But shed felt off all day. Her body wouldnt let her clean.

My head felt kind of tipsy almost like I was drunk, Johnson said.

So instead of gathering the test tubes and beakers and thermometers, she left the space as it was frozen in a state of suspended discovery.

Then the 55-year-old flicked off the lights in Room 217 and walked out of Franklin Learning Center, the Philadelphia high school where shed taught for 16 years.

I said,`Ill just take care of that when I come back Monday, Johnson remembered. I never came back Monday.

Johnson didnt know it then, but her teaching career had just ended.

The next six months would take her on an odyssey to the edges of medicine to the brackish place where science meets mystery. She would lose her hearing, her balance and, eventually, her independence.

Those six months would flip Johnsons life, and leave her with a gnawing question:

Did my school building do this to me?

That question confronts many Philadelphia teachers now more than ever.

In September, the citys teachers union announced that one of its own 51-year-old special-education instructor Lea DiRusso had been diagnosed with mesothelioma.

Mesothelioma is caused, in virtually every known case, by exposure to asbestos a toxic mineral once commonly used in insulation and other building materials. DiRusso worked for decades in two Philadelphia schools that had asbestos inside them, making it clear there may have been a link between her illness and her job.

DiRussos diagnosis presaged a flood of media coverage on asbestos and other potentially toxic substances inside Philadelphias public schools. It spotlighted the human cost of Philadelphias crumbling school infrastructure and fanned anxiety among educators, many wondering whether their own ailments trace back to something that lurked in their classrooms.

Unlike DiRusso, though, many of them will never conclusively know if working conditions caused their illnesses. Thats because mesothelioma is rare both in its prevalence and in the definitive link it has to an environmental toxin.

Like DiRusso, Lynn Johnson worked for years in a building with a troubling environmental track record. And she, too, had to retire abruptly.

But in every other way, Johnsons story is the photo negative of DiRussos.

Her illness is so mysterious, the medical establishment wont even call it a disease. It has no known cause. It offers more questions than answers.

Johnson and so many other teachers will likely never know if any of this could have been prevented.

Johnson, now 60, was destined to teach.

The Harlem native grew up playing playing school with her identical twin sister, Leslie. Their mother taught science in New York Citys public schools. And even though the pair studied to become dentists, they both circled back to the classroom.

Lynn Johnson started as a substitute in the School District of Philadelphia in 1990. The career appealed to her because of its flexibility, allowing her time to raise her two daughters. But it quickly turned into a calling an outlet for Johnsons natural charisma and gregariousness.

I became alive when I was in that classroom, Johnson said.

In 1999, she moved to Franklin Learning Center, or FLC, a high school just north of Center City, and became a full-time biology teacher.

Johnson thrived there. She won the Lindback Distinguished Teaching Award, one of the districts highest honors, and was a finalist for Philadelphia teacher of the year.

FLC has a proud history as a prize-winning school, but its four-story building, finished in 1909, has a more dubious past.

In 1996, students walked out of FLC because of suspected exposure to lead and asbestos. School district officials promised to demolish the structure and build a new one. They even put a price tag on the project: $30 million.

Talk of a new building lingered for years. Proposals went through modifications and tweaks and wholesale changes.

I dont remember a lot of the old-timers getting excited, Johnson said. I think that as you work with the School District of Philadelphia, you lose your trust in what they say theyre gonna do because sometimes it doesnt happen.

Indeed, the new building never happened. Instead, in 2010, the district set aside money to renovate FLC. It allotted about $3 million one-tenth of the original budget for the new building.

Johnson recalls finding mysterious dust in her room when workers renovated the classroom above her. She said she remembers leaks and crumbling tile and an off-putting directive from administrators to never drink water from the schools fountains.

When she heard the school was being renovated instead of destroyed, she felt more dread than relief.

Something in my head went, Oh, Lord, they disturbing up monsters, Johnson said.

Facilities issues surfaced again at FLC in December 2019, when the school district closed the school for several days after discovering damaged asbestos in an air shaft. The district has since reopened FLC, but parents and teachers staged a rally on the first day back to protest what they see as lingering hazards inside the building.

So far this school year, the district has closed six schools temporarily after discovering exposed asbestos. District officials say theyve upgraded their protocols for finding and remediating asbestos, although the citys teachers union has questioned the districts efficacy in several instances.

When she was teaching there, Johnson knew her high school was old and in need of repairs.

Thats not uncommon. The district has itself admitted that it has billions of dollars in deferred maintenance the legacy of old buildings and insufficient funds. Johnson figured that years in a century-old school might someday harm her, but it was never an acute concern.

Its in the back of your mind, wayyyyy in the back, Johnson said.

Then in November 2015, those years of low-grade unease turned into blinking red warning lights.

After Johnson left her classroom that Wednesday before Thanksgiving, she spent much of the holiday weekend unable to lift her head from the pillow. That Sunday, she tried to attend church with her family, but midway through the service, she turned to her husband.

I cant stand, she told him. I cant hear. Take me to urgent care.

An urgent-care doctor suspected she had a bad cold and gave her Sudafed. But the symptoms didnt subside.

Over the next six months, Johnson bounced from specialist to specialist. There was an infectious-disease specialist, a rheumatologist, and a pair of ear, nose and throat doctors. One by one, they crossed off potential ailments. It wasnt a cold. It wasnt Lyme disease. It wasnt. It wasnt. It wasnt.

Meanwhile, Johnson spiraled. She resigned herself to the possibility of death.

She went totally deaf in her right ear, and lost partial hearing in her left. She lost the ability to balance without a cane. She gave up driving because her eyes seemed unable to focus whenever she turned her head.

Im stuck in this body where I cant express myself. I cant move. I cant do anything, Johnson said. I fell apart.

In spring 2016, Johnson finally got a diagnosis of sorts: Cogans syndrome.

Cogans syndrome is so uncommon and ill-defined that it is not technically a disease. Its a cluster of symptoms that the medical establishment has christened with a name because those symptoms surface in enough patients.

It helps us so that we can group patients and think about how to treat them, said Peter Merkel, an expert on Cogans syndrome and the chief of rheumatology at the University of Pennsylvania. But it does tell us that perhaps were not as precise in our understanding.

Patients with Cogans syndrome have an autoimmune disorder, meaning their own immune system is attacking healthy tissue. If that autoimmune response is taking place in a persons inner-ear while also causing vertigo and eye inflammation, doctors may suspect Cogans syndrome.

There is no test that proves a patient has Cogans syndrome.

A lot of it is patient symptoms, crude measurements, and our gestalt of whats going on, said Steven Eliades, assistant professor of otorhinolaryngology at the University of Pennsylvania. [It] can be incredibly frustrating for the patient and, quite honestly, for me.

The symptoms patients experience often subside or at least stop progressing in response to steroids. Through that treatment, along with physical therapy, people with Cogans syndrome can make modest recoveries. But the condition is chronic and has no cure.

With the help of special grip socks, Johnson can shuffle around her house in Delaware County. Longer walks require a cane or wheelchair, particularly when shes out in public, on unfamiliar terrain.

Her hearing loss is permanent, making her a frustrated bystander in social settings where she used to thrive. Once the center of a room her room Johnson now needs other people to speak slowly, directly, and facing her so she can read their lips.

Johnson gravitated to science not because of what science tells us, but because of what it cannot tell us. She loved the notion that she could reach the limits of human explanation and stare out into the unknown.

I think it connects me to my spiritual awareness, said Johnson. [Science] made me closer with God because theres so much you dont know.

Now, the unknown greets her every day in the form of an illness that the brightest medical minds struggle to understand. She struggled for years to reconcile her awe of lifes mysteries with the reality of what this mysterious ailment had done to her life.

When this disease hit, bam, I questioned everything, Johnson said.

It should be stated plainly: There is no scientific evidence linking Johnsons illness with her work at Franklin Learning Center.

In fact, there is no accepted explanation for why anyone gets Cogans syndrome. It is a sickness without a known origin.

Johnson has long suspected, however, that her work environment somehow contributed to her illness.

When FLC was temporarily closed late last year, Johnsons fears resurfaced.

She suspects a link between her school building and her illness for two main reasons.

The first is her history of allergies. Johnson had severe allergies as a child that required her to receive three shots a week, she said. Allergies are, at heart, an immune-system response to things in the environment that dont typically trigger immune responses.

From this history of allergies, Johnson has concluded that her immune system is especially vulnerable to environmental triggers, and that shes the type of person who might develop an immune-related disease after spending years in an old building with environmental hazards.

My immune system was already on high alert, said Johnson. And its been on high alert for decades.

The second reason for Johnsons suspicions is genetic. She has an identical twin sister, Leslie Childs.

Childs does not have Cogans syndrome, nor does she display the same symptoms Johnson displays.

Childs lives in New York City and has never been inside FLC. The twins both believe that Childs lack of symptoms suggest that there is something in Johnsons environment that unlocked her illness.

Its night and day between her and I physically now, said Childs. Thats the difference. Our environment was different.

None of this is conclusive.

The medical literature is far too thin on Cogans syndrome to make a judgment on Johnsons suspicions.

Cogans expert Peter Merkel said hes seen some evidence that people with the syndrome are more likely to suffer from chronic allergies. But hes also seen some evidence that the illness may be brought on by a cold or infection. This is all from years of professional observation.

Theres no proof. For Johnson, there may never be proof of her theory one way or the other.

Its difficult for patients. Its difficult for physicians to deal with uncertainty, Merkel said. But thats a lot of what we have.

So why tell a story about a teacher who worked in an old school building and has a health condition with no known link to that school building?

In part, because so many stories about Philadelphia school teachers and illness will dead-end at this same point: We simply do not know.

We know that school buildings in Philadelphia have been poorly maintained. We know some teachers will eventually get sick. In individual cases, however, we often dont know if the first and second things have any connection to each other.

Take the case of Sharon Newman Ehrlich.

The veteran science teacher worked for years at Edison High School in North Philadelphia, one of the districts newer facilities.

In 2012, she transferred to Randolph Technical High School in the East Falls neighborhood. Almost immediately, she said, her lungs rebelled.

She developed acute breathing problems that made it almost impossible for her to last through the school day. A doctor eventually diagnosed her with occupational asthma. Ehrlich suspects something in the school triggered this response. She estimated shes made 35 doctor visits over the last seven years to see if she can turn up more answers.

After wheezing through part of the 2012-13 school year, Ehrlich never taught again.

She eventually wandered down a paper trail to figure out if there was something about the buildings history that could explain her sudden reaction. What she found would alarm anybody.

Randolph, it turns out, is located inside a renovated asbestos factory. That is not a typo. A current Philadelphia high school occupies the same site and structure as a converted asbestos factory.

The factory, run by a company called Asten-Hill Manufacturing, was sold in 1968. It opened as Randolph in 1975, just seven years later.

Could any of that explain Ehrlichs health conditions? Again, its almost impossible to know.

I just want to find out whats going on with my body, she said. I want to live as long as I can, and I wanted to teach as long as I could. I loved it.

Neither the teachers union nor the School District of Philadelphia could say how many city educators take early retirement due to medical conditions. And even if that number exists, it would take significant legwork to determine how many of those retirements had even a plausible connection to environmental toxins.

The union has repeatedly raised the specter of a teacher health crisis, drawing attention to DiRussos case and making allusions to cancer clusters.

But right now, there isnt any widespread evidence that staffers in Philadelphia schools are more likely to develop serious illnesses than employees of other school districts.

Theres also the risk of over-attribution, of teachers rightfully scared by media coverage of crumbling buildings being too quick to draw a connection between their health and their schools.

Sometimes, public panic over illness and environment can have serious, real-world consequences. Several experts mentioned the perceived and unproven link between autism and vaccines as a cautionary tale. Though the medical establishment has found no tie between the two, parent suspicions have lingered for decades. And those suspicions are starting to depress vaccination rates in some places.

Thats not to say theres no tie between old buildings and teacher illness only that panic without medical proof can be a slippery slope.

After all this, Lynn Johnson is left mostly with questions and unresolved emotions.

Physically, she said, shes improved or at least adjusted. She uses FaceTime now to make calls so she can read lips. Shes more adept with her cane after going to physical therapy. And she volunteers with an organization that raises awareness about diseases similar to hers.

Still, she cant teach. And it stings.

See the original post:
Philly teachers grapple with illness, school building conditions - WHYY

Read More...

How China Is The Future of Nanoscience – OZY

February 4th, 2020 12:47 pm

Everything about Chinas drive to become a leading innovator works on a giant scale. Ambitions are enormous, budgets are vast and the focus is widespread. And in many fields, its beginning to close the gap with U.S. and European institutions. But its in the study of materials on the scale of a billionth of a meter nanoscience that China is already fast overtaking its international rivals.

From cloning to cancer research, China is using nanoscience and nanotechnology innovation to drive some of the worlds biggest breakthroughs. In July, an international team of researchers led by Chinese scientists developed a new form of synthetic, biodegradable nanoparticle. Capable of targeting, penetrating and altering cells by delivering the CRISPR/Cas9 gene-editing tool into a cell, the nanoparticle can be used in the treatment of some single-gene disorders, as well as other diseases including some forms of cancer.

In a separate project, scientists at Chinas Nanjing University haveused nanoparticles to target and destroy abnormal proteins known to causebreast cancer. Tests in mice showed the treatment reduced the size of tumors byhalf compared to the control group. At the University of Science and Technologyof China, a team of researchers claims to have given mice infrared night visionby injecting nanoparticles into their eyes.

And at the State Key Laboratory of Robotics in the northeast city of Shenyang, researchers have developed a laser that produces a tiny gas bubble. This bubble can be used as a tiny robot to manipulate and move materials on a nanoscale with microscopic precision. The technology promises new possibilities in the field of artificial tissue creation and cloning.These innovations are backed up by a scale of research thats unmatched. In 2018, Chinese researchers were on their own responsible for 40 percent of all global scientific papers in the field, with the U.S. (15 percent) a distant second.

Nanotechnology supports biomedicine and quantum technology development and makes its way into everyday life through advancements in consumer electronics and artificial intelligence, all areas where China seeks global dominance. Being at the forefront of cutting-edge nano research greatly improves Chinas prospects for success, especially in biomedicine, where it has long trailed rivals.

Drug delivery, nanomedicine and tissue engineering are rapidly growing fields that rely on our ability to engineernanoparticles and biomaterialstargeted at specific cells, such as cancer cells,to enhance the therapeutic efficacy, says Dr. Omid Kavehei, deputy director of the University of Sydney Nano Institute.

Chinas gains could help it win critical patents in advanced research in fields like cancer, where the U.S. has historically led.

Strong state support in nanoscience as in tech fields such as artificial intelligence and robotics is also a key advantage for China, Bai Chunli, president of the Chinese Academy of Sciences (CAS), conceded publicly in August. The importance the government places on competitiveness in the field is underlined by its inclusion as a strategic industry in Chinas 13th Five-Year Plan, ensuring state funding and legislative and regulatory support. Nanotech research is also a key component of the ambitious Made in China 2025 initiative aimed at turning China into a high-tech manufacturing powerhouse.

Thats allowing China to find success in myriad areas of nanotechnology. A new nanomaterial invented by CAS scientists promises to eliminate millions of metric tons of liquid pollution and emissions from organic chemicals used in printing plates and ink. It is one of the headline acts for CAS as it drives to apply nanotechnology innovation to the development of consumer tech. So far, the project has landed $780 million in investment.

China still relies on collaborations with foreign institutions in most of the subfields of nanoscience and nanotechnology.

Shengfu Yang, University of Leicester

In an October 2019 paper published by science journalNano Energy, Dalian Institute of Chemical Physics announced the creation of a tiny lithium battery that is resilient to low temperatures, capable of operating at 80 percent efficiency at temperatures of -40 degrees Celsius. While the battery presents huge potential for industries from electric cars to mobile devices, the ability of the battery to operate at extreme temperatures is particularly important to the future of space technology.

Industry experts point to the return of foreign-trained Chinese researchers to the Middle Kingdom, lured by the promise of readily available funding, as an important factor of Chinas progress. The next step is for China to become self-sufficient in developing talent. Currently China still relies on collaborations with foreign institutions in most of the subfields of nanoscience and nanotechnology, says Shengfu Yang, nanochemistry professor at the University of Leicester. The nanoparticle that delivers the gene-editing tool into cells was developed in partnership with scientists at Tufts University in the United States, for instance.

Enhancing innovation in the private sector will also help China kick on, says Zheng Xiao Guo, professor of chemistry and mechanical engineering at the University of Hong Kong. State-funded institutions have played a far bigger role in nanotechnology innovations, and private institutions or enterprises in this area are not as strong, he says.

But the number of private companies driving nanotech product innovation is rapidly growing, Zheng concedes. Nanopolis, the worlds largest nanotech industrial zone, located in the eastern city of Suzhou, houses several private multinationals and new Chinese startups across nanotech fields. China now also leads the globe in newly established nanotech companies. In 2018, Tencent founder Ma Huateng joined a number of high-profile businesspeople in financing the establishment ofChinas first private research institute,Westlake University, with nanotech a main focus for research.

Private-sector involvement opens new and unique pools of funding and talent, and the focus is on applicable research even in a country like China, where state-sponsored institutions still dominate, say experts.

That combination of a growing talent pool and a state-sponsored desire to become a global leader, with an expanding private-sector ecosystem, will be hard for other countries to match. Chinas big leap in small science is just starting.

Go here to see the original:
How China Is The Future of Nanoscience - OZY

Read More...

Immix Doses First Patient in USA in its Phase 1b/2a Trial in Patients with Advanced Solid Tumors – Yahoo Finance

February 4th, 2020 12:47 pm

LOS ANGELES, Feb. 4, 2020 /PRNewswire/ --Immix Biopharma, Inc., announced today that the first patient in the USA was dosed successfully in its flagship phase 1b/2a clinical trial testing Imx-110 in patients with refractory solid tumors.To-date, the trial has accrued patients across tumor types. The expansion of the study to the US builds upon Immix' results from Australia, wherein six cohorts were dosed with no treatment-related serious adverse events observed and dose escalation is continuing.

The first US patient was dosed at Sarcoma Oncology Research Center in Santa Monica, California - led by Dr. Sant Chawla, a world renowned expert in sarcoma treatment and clinical research. Based on his extensive experience with anthracycline-based experimental therapies for sarcoma, including CytRx' Aldoxorubicin, Dr. Chawla shared his optimism for Imx-110 as an investigational candidate both from the standpoint of superior efficacy and a lower risk of cardiac complications associated with older formulations of doxorubicin.Dr. Chawla's colleague, Dr. Erlinda Gordon is the Principal Investigator leading the study at Sarcoma Oncology Research Center in Santa Monica.

Dr. Gordon is a Diplomate of the American Board of Pediatric Hematology/Oncology and previously a Tenured Associate Professor for 24 years at USC and currently a Professor Emeritus at the USC Keck School of Medicine, Los Angeles, California. She is a co-inventor of more than 150 patents in biomedical research, and patented the first targeted gene delivery system for cancer in the USA, Europe and the Philippines. She has authored more than 100 original peer-reviewed articles and served as Editor-in-Chief of the International Journal of Pediatric Hematology-Oncology, Director of the Red Cell Defects Program and the NIH-funded Comprehensive Hemophilia Center at Children's Hospital of Los Angeles and the NIH-funded Children's Oncology Group. Dr. Gordon was co-founder of two biotechnology companies and is a pioneer in the development of targeted gene therapy products.

For more information on the Imx-110 study, please visit clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT03382340.

Immix also has an open call for investigator initiated studies where the company will provide Imx-110 at no charge.

About Imx-110Imx-110 is a first-in-class combination therapy designed to inhibit cancer resistance and evolvability while inducing apoptosis. Imx-110 contains NF-kB/Stat3/pan-kinase inhibitor curcumin combined with a small amount of doxorubicin encased in a nano-sized delivery system for optimal tumor penetration. The nanoparticle is tunable in that it can be bound to various targeting moieties, allowing it to deliver even more payload to tumors or other cell populations of interest, if needed. Imx-110 showed preclinical efficacy in glioblastoma, multiple myeloma, triple-negative breast, colorectal, ovarian, and pancreatic tumor models with the mechanism of action being a 5x increase in cancer cell apoptosis compared to doxorubicin alone, and a wholesale shift in the tumor microenvironment post administration.

About the CompanyImmix Biopharma, Inc. is a privately-held, biopharmaceutical firm focused on developing safe and effective therapies for cancer patients. The company was founded by Vladimir Torchilin, Ph.D., D.Sc., Director of the Center for Pharmaceutical Biotechnology and Nanomedicine at Northeastern University; physician-scientist and clinical researcher Ilya Rachman, MD, PhD, MBA; and Sean D. Senn, JD, MSc., MBA, a senior biotechnology patent attorney. Immix's founding investor is a family office focused on harnessing scientific advances in order to engineer transformative and effective cancer treatments. For more information visit http://www.immixbio.com.

Media ContactRyan Witt+1 (888) 958-1084info@immixbio.com

View original content:http://www.prnewswire.com/news-releases/immix-doses-first-patient-in-usa-in-its-phase-1b2a-trial-in-patients-with-advanced-solid-tumors-300998208.html

SOURCE Immix Biopharma, Inc.

Read the rest here:
Immix Doses First Patient in USA in its Phase 1b/2a Trial in Patients with Advanced Solid Tumors - Yahoo Finance

Read More...

NanoViricides: A History Of Producing Headlines Without Producing A Product – Seeking Alpha

February 4th, 2020 12:47 pm

The Wuhan Coronavirus has rapidly become a global health crisis and is producing hourly headlines. As a result, many of the vaccine tickers started to experience parabolic reactions as investors speculate on who will benefit from the growing health crisis. NanoViricides (NNVC) is one of these tickers and has rocketed from ~$3 to around $19 per share. On January 30th, NanoViricides announced it is has already initiated a program for developing a treatment for the 2019-nCOV." In addition, the company believes that their platform technology allows them to possibly have the most rapid pathway for new drug development against viral diseases. This triggered a sharp spike in the share price and has investors keeping a close eye on NNVC for their next move. Unfortunately, the company has yet to gain support from governmental and international agencies, so it doesnt appear NanoViricides is going to be in lead considering Moderna (MRNA) at least has a clinical collaboration with NIH. What is more, the company has started several pipeline programs but has yet to put one into human trials. Consequently, I believe investors need to be cautious around this ticker and should be skeptical about its ability to be a long-term investment.

I intend to provide a brief background on the companys platform technology and pipeline programs. In addition, I discuss my concerns around the companys technology and the ability to get one of their programs through the FDA. Moreover, I recap the companys history of publicizing their intention to develop a therapy for the latest outbreak but has yet to get one of these programs into the clinic.

NanoViricides is committed to the advancement of nanomedicine drugs in the battle against viruses. The companys nanoviricide platform technology intends to develop first-in-class drugs to envelope virus particles, which should block a virus from infecting a healthy cell and will eventually destroy the virus.

Figure 1: NanoViricide Mechanism of Action (Source: NNVC)

NanoViricides has its own c-GMP capable manufacturing facility that can be used to produce their own product candidates for both clinical and commercial use. In terms of pipeline programs, the company has multiple preclinical programs that are moving closer to an IND and into human trials (Figure 2).

Figure 2: NanoViricide Pipeline (Source: NNVC)

At the moment, the company is focused on bringing their NV-HHV-101 HerpeCide program into human trials. This would be the companys lead product candidate for a topical treatment for shingles rash and would be the companys first clinical program. According to the company, NV-HHV-101 had positive GLP Safety/Toxicology and non-GLP studies. Unfortunately, the company hasnt been able to produce any animal models in order to evaluate their dermal treatment but has been using ex vivo human skin organ culture model studies to determine some safety and efficacy. NanoViricides is preparing to file an IND and transition into a clinical-stage biotech.

Once NV-HHV-101 is in the clinic, the company expects to advance their HSV-1 cold sores and of HSV-2 genital ulcers programs. In addition, the company has several preclinical programs that include therapies for HIV, Dengue, Ebola, Bird Flu. These programs are at different stages of preclinical development and have demonstrated safety in animal models. According to the company, their anti-HIV drug candidate has demonstrated complete suppression of the HIV virus in mouse models, which would lead to a functional cure.

My Concerns

Does the NanoViricide entice or attack a virus? After reading through the companys presentation, I couldnt come to a conclusion about how their platform works. The company has illustrated that their NanoViricides attacks and envelopes the virus (Figure 1). However, they have also stated that the NanoViricides fools the virus that it is a host cell and then entraps the virus. Perhaps the NanoViricides work both ways, but it still has me wondering about how it is supposed to act inside the bodya human host cell is astronomically bigger than the virus that is attempting to infect it (Figure 3).

Figure 3: Size Comparisons (Source: Research Gate)

Viruses are measured in nanometers and human cells are measured in microns, yet, the NanoViricide is attempting to trick the virus to thinking it is human cell. Indeed, a virus doesnt decide to attach to a human cell because of its size but rather surface receptors. Still, I dont see it as it being tricked but rather just getting stuck and consumed...which makes me wonder about the size of a NanoViricide...How big of a virus can it cover? Can multiple NanoViricides work on one virus?

How does the NanoViricide destroy the virus? Viruses are quite resilient for just being RNA or DNA encapsulated in a protein coat. A virus requires host cells to carry out the remaining life processes in order to reproduce. This gives our bodies a chance to identify and destroy viruses with our innate and adaptive immune systems by several complex mechanisms. So, an explanation of how a NanoViricide destroys a virus needs to go beyond it encapsulates and destroys. The company explains that the NanoViricide delivers a devastating payload of active pharmaceutical ingredients API into the virus particle, thereby completely destroying the enemy. What is this API? Does it cause cytotoxicity? Is it relying opsonization? The company has a slide (Figure 4), that shows NanoVircide dismantling the capsid.

Figure 4: NanoViricide Dismantling (Source: NNVC)

Admittedly, the company is attempting to be one of the leaders in nanomedicine, so perhaps the mechanisms are beyond me and contemporary medicine. Unfortunately, we cant rely on currently approved products or science to understand how NanoViricide works, which doesnt bode well in my opinion. Contemporary vaccines, antibodies, and anti-viral drugs are effective against viruses, so I have to imagine health agencies and organizations are going to side with the standard-of-care modalities rather than take a chance with unproven technology.

Another issue I have with their technology is how they plan to run clinical trials for some of their pipeline programs. Take their shingles cream candidate, which is intended to be a topical treatment for the shingles rash. How is the company supposed to run a clinical trial for this? What would be an inclusion or exclusion trial for this? How would they know if it is better at clearing up a rash vs. placebo alone? A shingles rash appears abruptly and can last several weeks, so, determining if NanoViricides were able to shorten or diminish the impact of the rash would be difficult to measure. I have the same issue with infectious viruses, where the company is attempting to prove their NanoViricides work against a dangerous virus. With vaccines, companies are able to determine their ability to stimulate the immune system and elicit some seroprotection without the subject being infected with the virus. NanoViricides is not a vaccine, so the subject would have to be infected with the Wuhan Coronavirus in order to determine if it is effective against the virus. Overall, I see the company having a hard time clearing some of these regulatory hurdles and being able to prove its product works the way it is intended.

The other concerning issue is the companys history of developing the current global health crisis and has yet to get that program into the clinic. The company started to develop an Avian Bird Flu drug back in 2006, and yet, it has yet to hit the clinic. The same can be said for their Dengue program that was started in 2007, and the same with Ebola in 2008 and 2014. In addition, the company promoted their efforts against MERS in 2014 and has been attempting an HIV program for several years. Unfortunately, none of these programs have made it into the clinic for human trials but investors cash has made it into the companys bank account. It appears the company takes advantage of any major global health crisis by claiming they have a potential product and they are working hard to quickly progress their NanoViricides against the most recent headline virus. In reality, the company doesnt move out of discovery and preclinical studies. Sadly, investors have been enticed by the prospects of investing in a company that has an answer to the current scare, only to experience dilution that has devastated the share price over the years (Figure 5).

Figure 5: NNVC Weekly Chart (Source: Trendspider)

Even if the company wanted to push forward with development and start human trials, it will need a large amount of cash to get the ball rolling. What is more, the company would most likely need to secure commercial partners to produce and distribute their products. Admittedly, the company just raised about $7.5M in a public offering after the stock popped once the Wuhan virus started to catch the publics eye. Still, the company will most likely need some additional funding to get one of their product candidates through the FDA.

NanoViricide might be working on a potential treatment for the Wuhan Coronavirus, but investors need to be cautious here. The company has a 15-year history of promoting their attempts to develop a leading therapy for the latest virus but has yet to get one of these programs into human trials. Even if the company is able to develop a potential candidate, it is going to need the help from government agencies and institutions to be used and it looks as if some of the worlds biggest pharmaceutical and biotechs are already starting to send some of their anti-viral products to China to help with the outbreak. In fact, Johnson & Johnson (JNJ) is already working on a vaccine and has donated some of their HIV medications. What is more, NanoViricides is not even listed on a CNBC list of companies working on a Coronavirus vaccine or drug (Figure 6).

Figure 6: List of Coronavirus Companies (Source: CNBC)

Considering these points, I would advise investors to wary of investing until the company is able to get an IND and reports their first human data. Until then, I expect shorts to start piling on once the market realizes the company is reusing its old playbook of promoting a program and never following through with it.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

More:
NanoViricides: A History Of Producing Headlines Without Producing A Product - Seeking Alpha

Read More...

4 Crazy but Effective Ways to Save More Money This Year – Nasdaq

February 4th, 2020 12:46 pm

It's no secret that Americans aren't doing all that well in the savings department. An estimated 39% of U.S. adults don't have the money on hand to cover a $400 emergency, and 45% of Americans have no money earmarked for retirement savings.

If your savings efforts have been far from fruitful in recent years, it's time to do better -- even if that means going to a bit of an extreme to get there. Here are a few far-out but effective methods of boosting your savings -- and buying yourself the financial security you're currently missing.

IMAGE SOURCE: GETTY IMAGES.

If you're not familiar with no-spend periods, they involve not forking over so much as a dime on non-essentials for different periods of time. It's common to have an occasional no-spend week or no-spend month, but if you're really intent on boosting your savings, you may want to extend that restriction for a full year. That's right -- no restaurant meals, non-work clothing, or paid entertainment for an entire 12 months.

Will that be difficult? Absolutely. But imagine you currently spend $600 a month on dining out, leisure, apparel, and other items you enjoy having but can technically live without. In the course of a year, you'll be $7,200 richer.

Housing is the typical American's greatest monthly expense, so if you're able to reduce it substantially, you're apt to boost your savings in a very meaningful way. Imagine you currently rent a three-bedroom, 2000-square-foot apartment with your spouse and child for $2,000 a month. If you were to downsize to a one-bedroom (yes, you read that correctly) that takes up 800 square feet, you might reduce your rent to $1,000.

Will living in cramped quarters for a year be easy? Not at all. But if it saves you $12,000, it's a sacrifice worth making.

It costs $9,282 a year, on average, to own a vehicle, according to AAA. If you're willing to give yours up, you could wind up banking that much cash in the course of a year instead.

Now if you live in an area where public transportation is abundant, that's not such a huge ask. But if you live in suburbia, it could prove more challenging. That doesn't mean it can't be done, though. You could consider carpooling with your spouse (meaning, downsize from a two-car household to a single car), catching rides with friends or colleagues, or biking to and from work if that's a reasonable thing to do (if your office is 40 miles away, it's not).

Will giving up a car limit you logistically and socially? Probably. But think about it this way -- if it's harder to get around, you may be less inclined to dine out or spend money on entertainment, which will help your savings efforts.

The typical American spends $3,456 a year on restaurant meals and food outside the home, according to the U.S. Bureau of Labor Statistics. But restaurants generally charge a 300% markup on the items they serve, which means that if your spending is in line with the typical American's, you could save yourself close to $2,600 in the course of a year by cooking every meal you eat at home.

Will that constitute a time investment? It sure will. But you never know -- you may discover that you enjoy cooking your own food, and that doing so is healthier for you anyway.

If you're doing reasonably well financially -- meaning, you're on track for retirement and have a healthy emergency fund -- then there's certainly no need to go to any of the above extremes (unless, of course, you happen to love a good challenge). But if your near-term and long-term savings are virtually nonexistent, then you may need to take drastic measures to build them up. The good news? You don't need to commit to these extremes for a lifetime. Make any of the above moves for a single year, and your savings could easily take a turn for the much improved.

The $16,728 Social Security bonus most retirees completely overlook If you're like most Americans, you're a few years (or more) behind on your retirement savings. But a handful of little-known "Social Security secrets" could help ensure a boost in your retirement income. For example: one easy trick could pay you as much as$16,728 more... each year! Once you learn how to maximize your Social Security benefits, we think you could retire confidently with the peace of mind we're all after.Simply click here to discover how to learn more about these strategies.

The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Read the original here:
4 Crazy but Effective Ways to Save More Money This Year - Nasdaq

Read More...

AgeX Therapeutics to Collaborate with University of California, Irvine on Neural Stem Cell Research Program for Huntingtons Disease and Other…

February 3rd, 2020 4:45 pm

AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced a research collaboration with the University of California, Irvine (UCI) using AgeXs PureStem technology to derive neural stem cells, with the goal of developing cellular therapies to treat neurological disorders and diseases for which there are no cures. The collaborations initial R&D work, expected to take approximately one year, will be conducted in the UCI laboratory of Leslie Thompson, PhD, Chancellors Professor of Psychiatry & Human Behavior and Neurobiology & Behavior, a leading researcher in the field of Huntingtons disease and other neurological disorders, under a Sponsored Research Agreement handled by the Industry Sponsored Research team at UCI Beall Applied Innovation. The initial focus will be on Huntingtons disease, while other potential targets may include Parkinsons, Alzheimers, and stroke.

The primary goal of the research will be to develop a robust method of deriving neural stem cells from pluripotent stem cells in sufficient quantity and with sufficient purity and identity for use in cell-based therapy. Professor Thompsons laboratory has already accumulated safety and efficacy animal data that may support an IND submission to the FDA as early as 2021 for the commencement of clinical trials to treat Huntingtons disease.

"We look forward to utilizing AgeXs cell derivation and manufacturing PureStem technology, with its many potential advantages, including industrial scalable manufacturing, lower cost of goods, and clonal cells with high purity and identity. Our goal is to have an improved neural stem cell production method ready within a year to move into clinical development," said Professor Thompson.

"We are absolutely delighted to start this exciting collaboration with Professor Thompson, who has worked tirelessly over her career to develop a neural stem cell product candidate for Huntingtons disease and who has already generated preclinical animal data that may support the initiation of clinical studies," said Dr. Nafees Malik, Chief Operating Officer of AgeX. "Moreover, we are very excited to be entering the field of neurology, which has huge clinical and commercial potential. Neural stem cells may be very useful in other neurological disorders that are common in aging demographics, such as Parkinsons, Alzheimers and stroke."

"This is an example of the kind of collaboration we will be seeking under our newly-unveiled collaboration and licensing strategy, which is to run parallel to our in-house product development," said Dr. Greg Bailey, Chair of AgeX. "We will be collaborating with a world leader in their field on a research project which is close to the clinic."

The collaboration includes an opportunity for AgeX to organize a company to be jointly owned with Professor Thompson and other researchers to pursue clinical development and commercialization of cell therapies derived using licensed inventions arising from the research program, as well as certain patent pending technology for neural stem cell derivation, and certain technical data, including animal data, to support IND submissions.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly-defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies in the body. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan and is seeking opportunities to establish licensing and collaboration agreements around its broad IP estate and proprietary technology platforms.

Story continues

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

Forward-Looking Statements

Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates" should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries particularly those mentioned in the cautionary statements found in more detail in the "Risk Factors" section of AgeXs Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Further, in the case of AgeXs new neural stem cell program there can be no assurance that: (i) any new cell derivation methods will be invented in the sponsored research program, (ii) any derivation methods that may be developed will be sufficient to derive neural stem cells in quantities and of purity suitable for clinical use and commercialization, (iii) that any new inventions or existing technology will be licensed on commercially favorable terms, (iv) that any neural stem cells derived for therapeutic use will be shown to be safe and effective in clinical trials, and (v) that any neural stem cells derived for therapeutic use will be successfully commercialized even if clinical trials are successful. Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200203005261/en/

Contacts

Media Contact for AgeX: Bill Douglass Gotham Communications, LLC bill@gothamcomm.com (646) 504-0890

Go here to read the rest:
AgeX Therapeutics to Collaborate with University of California, Irvine on Neural Stem Cell Research Program for Huntingtons Disease and Other...

Read More...

SASpine to offer Stem Cell Therapy – Yahoo Finance

February 3rd, 2020 4:44 pm

SAN ANTONIO, Feb. 3, 2020 /PRNewswire/ -- SASpine is now offering cutting edge Stem Cell Treatments to patients. For the past several years Dr. Steven Cyr, Mayo Clinic Trained Spine Surgeon, has been researching the benefits of stem cells in the treatment of multiple medical conditions including spinal disorders, specifically, conditions which involve spinal cord injury, degenerative disc disease, herniated discs, and as a supplement to enhance the success of Spinal fusions when treating instability, deformity, and fractures of the spine.

Steven J. Cyr, M.D., is a spine surgeon who has gained a reputation for surgical excellence in Texas, throughout the nation, and abroad.

Dr. Steven Cyr has been treating patients using growth factors and stem cells contained in amniotic tissue and bone marrow aspirate to provide a potential for improved success with fusion procedures, when treating herniated discs, and for arthritic or damaged joints, with remarkable success. "The goal of any medical intervention is to yield improved outcomes with the ideal result of returning a patient to normal function, when possible," states Dr Cyr. He went on to elaborate that there are times when only a structural solution can solve problems related to spinal disorders, but even in that scenario, the use of stem cells or growth factors derived from stem cell products can possibly improve the success of surgical procedures. "I have patients previously unable to jog or run return to normal function and athletic ability after injections of growth factors and stem cell products into the knee joints, hip joints, and shoulder joints," he said. "This includes high-level athletes, professional dancers, and the average weekend warrior."

There may be promise in treating patients with spinal cord injury as well. SASpine CEO, LeAnn Cyr, states, "There are reports of patients gaining significant neurological improvement after being treated with stem cells." Dr Cyr continues, "Most patients with spinal cord injuries resulting from trauma also have mechanical pressure on the nerves that result either from bone fragments or disc material compressing the spinal cord that needs to be removed along with surgical stabilization of the spinal bones. There's significant potential that stem cells bring to the equation when treating these types of patients, and I am excited about the potential that these products offer to the host of treatments to address spinal conditions and arthritic joints."

For more information about SASpine's Stem Cell Treatment Program, visit http://www.saspine.com or call (210) 487-7463 in San Antonio or (832) 919-7990 in Houston.

Related Linkswww.facebook.com/saspinewww.instagram.com/surgical.associates.in.spine

If you've been living with back pain, you're not alone. Here at SASpine, we have experienced spine specialists who are committed to improving your quality of life. (PRNewsfoto/SASpine)

View original content to download multimedia:http://www.prnewswire.com/news-releases/saspine-to-offer-stem-cell-therapy-300997355.html

SOURCE SASpine

Go here to see the original:
SASpine to offer Stem Cell Therapy - Yahoo Finance

Read More...

Page 719«..1020..718719720721..730740..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick